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INTRODUCTION
Japanese encephalitis (JE), a mosquito-borne viral
infection, remains a major public health problem in Asia,
reportedly causing 16,000 to 50,000 acute encephalitic
episodes and 5000 to 10,000 deaths annually. The syn-
dromes caused by the virus range from encephalomyeli-
tis to mild febrile illness. Where JE is endemic it is prin-
cipally a disease of children, the highest rates occurring
in children aged under 10 yr living in rural areas, espe-
cially where rice is grown and pigs are reared1. Further-
more, long-term neurological disability occurs in an ap-
preciable fraction of JE survivors2.
The disease is spread by the bite of female Culex
mosquito and the virus is harboured and multiplied in
pigs and birds. The main control strategies are vector con-
trol and surveillance but vaccination is most effective of
all. An effective vaccine is available since as early as 1941.
However, due to limited productivity and high price it was
not affordable for widespread public health use. In Japan
and the Republic of Korea, national programmes of rou-
tine immunization with inactivated JE vaccine have nearly
eliminated the disease, even in the areas of highest risk1.
In India, at present 15 states report JE (under AES–
Acute encephalitis syndrome) cases and among these
states Uttar Pradesh is the worst affected. In U.P. alone
from 2003 to 2009, a total of 19,644 cases and 4331 deaths
have been reported. In 2005, a massive outbreak caused
>6000 cases and 1500 deaths in the state following a vac-
cination programme was initiated in 11 of the highest risk
districts of the country in 2006, 27 districts in 2007, 22
districts in 2008 and 30 districts in 2009. Children be-
tween the age group of 1 and 15 yr were vaccinated with
a single dose of SA14-14-2 vaccine. In an earlier experi-
ment vaccination has shown very encouraging results in
the control of the disease in the states of Tamil Nadu and
Andhra Pradesh. Thus, to control JE, the Government of
India has decided to introduce and expand JE vaccina-
tion to the JE endemic districts of the country in a phased
manner3.
Vaccination against JE is proven to be the most ef-
fective measure for the control of the disease. However,
vaccine is limited in supply, costly in use and application
and its introduction will add resource burden to the health
system. Moreover, when the vaccine is introduced in the
routine immunisation it will require a constant resource
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Background & objectives: Japanese encephalitis (JE) is a major cause of child mortality and disability in the state
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investment for a sustainable period of the time. Before
this investment of resources can be committed the deci-
sion makers must be informed about the potential return
from the investment and its comparison with the return
from the alternative uses of these resources in other pub-
lic projects. In economics, this purpose is best achieved
by a cost benefit analysis. Only when net benefit from
the investment is positive (that is benefit is more than
cost) then the project should be undertaken. Moreover,
the internal rate of return should be estimated so that the
project can be compared across the sectors. This study is
an attempt to evaluate the cost of introducing the JE vac-
cination programme in routine immunization programme
to its potential benefits over a period of 5 yr in the state of
Uttar Pradesh.
The study will help to understand the resource allo-
cation required to undertake and continue the project. It
will also describe the various cost and benefits associ-
ated with the intervention. The economic information will
be helpful to the programme managers, policy makers
and those working in the area of JE control.
METHODS
Research setting
Uttar Pradesh which is the paddy growing Terai area
lies between latitudes 24° and 31° north and longitudes
77° and 84° east and is a completely land locked state.
Uttar Pradesh is the most populous state in India, account-
ing for 16.4% of the total population of the country. Popu-
lation density of this state is 689 persons/km2 while it is
324 persons/km2 for the country. Children aged 0 to 6 yr
make up 18.35% of the population, of which 9.58% are
males and 8.77% are females, while approximately 40%
of the total population belongs to the 0–12 yr age group.
The rural population is 79.22%4. There are three distinct
seasons, summer (March to June, temperatures ranging
from 27.5°–32.5°C, with a max 45°C); monsoon (July to
October, with rainfall of 1000–2000 mm in the east, and
600–1000 mm in the west); and winter (November to Feb-
ruary, temperatures ranging from 12.5°–17.5°C). The en-
tire state has a tropical monsoon climate.
Description of interventions
The Government of India has decided to introduce and
expand JE vaccination to the endemic districts of the coun-
try in a phased manner based on the following strategy.
A one-time mass campaign will be performed to cover
all children in the age group of 1–15 yr in the districts.
Followed by integration of the JE vaccine into the routine
immunization programme to cover the new cohort (chil-
dren attaining >1 yr of age) in the districts covered previ-
ously under the JE vaccination campaign. The children
between 1 and 2 yr of age would be administered the JE
vaccine along with the DPT booster dose, under the rou-
tine immunization programme. Both rural and urban popu-
lation will be covered. For this purpose live attenuated
SA14-14-2 JE vaccine manufactured at Chengdu Institute
of Biological Products (CDIBP), China will be procured.
As per the operational guidelines of the Government of
India, the introduction of vaccine in routine immunization
would not require any major capital infrastructure. The
recurrent expenditure is mostly the cost of the vaccine
procurement, storage, distribution and monitoring. In
0.005% of the cases, the vaccine causes adverse reaction
which requires the treatment3.
All the children not receiving vaccination are at risk
of developing the disease. The disease requires treatment
by admission in the hospital. The treatment of JE is non-
specific, prolonged, costly and is associated with uncer-
tain results. Under present policy a case of JE is admitted
in hospital and receives treatment free of cost. However,
household has to bear the expenses associated with the
transport, food, some medications and other associated
costs such as investigations. Moreover, households face
substantial loss of income as opportunity cost while pro-
viding care to the patient. For the purpose of evaluation,
the study will consider the vaccination and the treatment
as two different economic activities. The cost of vaccina-
tion negates the cost on the treatment of the disease.
Study design and conceptual framework
This study is an economic evaluation of health inter-
ventions and tries to compare social costs and benefits of
the programme using standard economic methods. This
is a prospective study which estimates the future costs
and benefits using cross-sectional data from various
sources after triangulation under a set of strong assump-
tions. The interventions constitute an economic activity
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and a typical production function can be used as a con-
ceptual framework for the study (Fig. 1).
Social cost of the intervention
For the purpose of evaluation we only calculate the
cost of introducing the vaccine in the routine service and
to maintain it. We will not include the cost of one time
mass campaign in the beginning of the programme to
avoid the huge escalation of cost for the five years project
under study. We also assume that the vaccine will not
invite any significant capital expenditure under present
system. However, recurrent expenditure at regular inter-
val will be required mostly for the personnel, storage,
transportation and distribution, monitoring and adminis-
trative cost. The data pertaining to such costs were
collected from the government health system through
the appropriate method like interview, observation and
departmental records. Wherever possible items and
consumables were valued at market prices else shadow
pricing was used. The overhead costs were allocated as
per units consumed. Thus, standard methods of econom-
ics were used to collect cost data as suggested by stan-
dard literature5. Due to adverse reaction of the vaccine in
certain cases the society bears some additional cost of
treatment which is also added to the cost of vaccination.
For the purpose of study, the cost of treatment of a ad-
verse reaction is considered to be equal to the cost of treat-
ment of JE case as data for treatment of adverse reaction
was difficult to calculate.
The cost of treatment per case of JE was calculated by
interviewing a key respondent from the households of the
patients undergoing treatment at B.R. Ambedkar Hospital,
Gorakhpur, Uttar Pradesh. For provider side-cost estima-
tion appropriate method as in the case of estimation of vac-
cination was used. All important capital costs were utilised
and appropriate valuation methods were also employed6.
Social benefit of the intervention
Principle effect of vaccination is protection from the
disease and its severe consequences. Thus, vaccine pre-
vents death, disability and discomfort. Thus, benefits from
the vaccine are multiple, however, in this study we only
quantify the benefits in the form of cost saved on treat-
ment of the disease. We calculate total cost saved on treat-
ment of the disease avoided due to vaccination. Net value
is thus, determined by properly discounting the costs to
the base year of 2011.
Method of analysis
The data were entered in a spread sheet (MS excel)
calculator and analyses were run to calculate the annual
cost of vaccination (unit cost of vaccine applied to the
total numbers of vaccinations done). The number of vac-
cine vials required is calculated as per the method given
in the Government of India’s operational guideline on JE
vaccination. The successive annual costs were discounted
using social discount rate of 10% to get the total dis-
counted cost of vaccination. Similarly, the total benefit
was estimated by estimating the total number of cases
avoided for the future year. For this purpose, we used the
effectiveness ratio of the vaccine at 98% and vaccination
coverage equal to that of DPT vaccine as on implementa-
tion vaccine will be administered along with DPT. This
way we can understand the total number of JE cases in
the presence of a JE vaccine in a given year. Next using a
time series analysis we can get a rough estimate of num-
ber of JE cases that would occur in future years without
JE vaccination. The difference of cases without vaccine
and that with vaccine gives the estimate of number of JE
cases avoided. This number multiplied with the total cost
of treatment of JE gives the value of resources saved.
RESULTS
Demographic and socioeconomic profile of the respon-
dents
A total of 120 cases of JE were included in the study
for the purpose of estimation of household cost for treat-
ment of JE. Average age of patients was 6 yr (range 2–22
yr). About 62% of cases were males and >67% belonged
to households with gross monthly income < ` 5000 per
month, 26% between ` 5000 and 10000, and only 7%
reported monthly income above ` 10000. The median
monthly household income was ` 3200 (range 2400–
50,000 per month). Almost 33% of the households sourced
their expenditure from loan and 50% relied on their earn-
ings or savings. Around 10% cases were financed by close
relatives or friends (not loan but as a gesture of solidar-
ity). Rest refused to disclose their source of expenditure.
The median duration of hospitalisation was 12–13 days.
Only 24% of cases directly visited the government hos-
pital without visiting anywhere else.
Purchaser side cost of treatment of JE
The purchaser side cost was calculated as direct and
indirect cost7 and it has a varying range from ` 5800–
1,46,378. This huge variation was due to the large num-
ber of patients who went for private health care treatment
before coming to the government hospital. One more rea-
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the duration it affects the respondent as larger the dura-
tion larger is the purchaser side expenses.
Average (median) of total direct cost (both medical
and non-medical) as borne by the patients was around
` 13212 (range ` 3781 to ` 74876) and indirect cost was
averaged (median) around ` 22,427. Direct cost consti-
tuted almost 37% of the total purchaser side cost. The
largest share of direct cost was constituted by medical cost
(50%). Table 1 summarises the total purchaser side cost.
This value of total indirect cost incorporates the prod-
uct of total number of workdays lost (due to illness and
during recovery phase) multiplied by prevailing wage rate
as per to patient’s occupation. For unskilled and unem-
ployed patients in the productive age group the wage rate
of unskilled labourers as decided by the district adminis-
tration was used. On an average (mean) a case of JE lost
587 h of work per episode of the disease. Value of loss of
income (opportunity cost) to the patient’s relative and
household was arrived at ` 14,257 (range ` 2400–29000)
which is inclusive of cost to one-to-two full time atten-
dant with the patients, cost to those who regularly visited
the patients and the perceived cost to the households in
which some dependants were left unattended back home
because person who looked after them was visiting this
patient in hospital. These indirect costs constitute almost
63% of the total cost borne by the household. On an aver-
age 212 days of school/instructional days (nearly 848 h
of learning time) were lost for the patients in the age group
of 5–15 yr of age.
Provider side cost
Provider side cost was collected from the B.R.
Ambedkar Medical College, Gorakhpur. Here a special
ward is provided for the treatment of JE cases. Unit cost
of treatment of per case was calculated using step down
approach as done in standard health economics study8.
Unit cost of treatment of a JE patient was found to be
nearly ` 16900. Table 2 represents the break-up of pro-
vider side-cost of treatment.
Unit cost of vaccination
According to the data from international organisation
People for Assessment of Technology in Health (PATH)
which procured the vaccine from China the price of one
vaccine from provider perspective will be around ` 11.70.
For ease of calculation we can keep other costs at zero as
we know that vaccine will be administered at 18 month
along with booster dose of DPT. Thus, we keep the
charges of logistics and other expenses inclusive in the
price of ` 11.70 (Table 3).
Benefits of intervention
We assume the benefit to be limited to the cost saved
on treatment due to vaccination. This is a very crude ap-
proach yet we can argue that if without considering the
other benefits the net value is positive then we need not
bother about those benefits. Total estimation of JE cases
in the absence of vaccination is done by a time series
analysis using previous year incidence data from
Table 2. Unit cost of treatment of JE case
Items Total Per diam Per patient
expenditure per capita cost of
for 2008–09 curative
(in `) treatment
(in `)
Salary 14040107.2 230.7714 6421.6
Allowances 4910728.66 46.06179 1309.73
Travel and daily 11737.68 1.037143 25.04
allowances
Laundry 45446.26 4.018929 82.53
Utilities 260517.08 25.66929 518.74
Fuel 183405.5 16.20536 259.75
Maintenance 808455.46 32.43321 1567.13
Stationary and others 242095.9 21.39107 421.95
Printing 9977.28 8.815714 246.84
Miscellaneous 106576.04 9.593571 168.62
Drug 1650227.34 211.1882 3913.27
Overhead 5707586.94 23.43107 812.07
Annualised capital 7556751.4 44.48929 1141.7
Total cost 35533612.74 675.106037 16888.97
Table 1. Total purchaser side costs for JE
Cost category Median Range %
(`)( `)
Direct cost
Total medical cost 6638 50
Transportation and 4430 33
accommodation
Food 1520 11.5
Loan 624 4.7
Sub total 13212 3781–74876 37
Indirect cost
Wage loss to patient 8170 1289–94381 36
Wage loss to attendants/relatives, 14257 2400–29000 64
cost of attending the
dependents back home
Sub total 22427 63
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DISCUSSION
The result showed that the benefit of vaccination was
much higher than the cost of it. The return on investment
is surprisingly high and it is rarely a return from any other
such projects. Together these two values make the inter-
vention highly recommended. Although this finding is
based on various assumptions but still various benefits
were not taken into consideration which are definitely
much more than present return. Uttar Pradesh has a large
population and incidence rate of JE is ` 15 per 10,000 for
allover India but owing to its high population number of
children at risk is more in Uttar Pradesh than anywhere
else in the country, thus the gain of benefit will be more
in Uttar Pradesh.
There is clear indication that the cost burden by pur-
chaser in respect to availing curative care is more than
the burden by the provider side, thus, in the case of cost
of provider for vaccination is one sided but it still gives a
huge benefit to the purchaser. Almost all the respondents
had catastrophic expenditure due to JE (>90%). It could
be attributed due to high cost of travelling and duration
of the disease. Around 65% respondents had additional
cost of private health care which on adding will increase
the costing on treatment side very high but in general even
though they were given free service at the government
hospital still they bear various expenses.
This study can serve as an ex-ante evaluation of vac-
Table 3. Total unit cost of vaccine on treatment of JE (in `)
Year No. of persons Unit cost of Total cost of Discount
vaccinated one vaccine vaccination price
2011 1084761 11.70 12691704 12691704
2012 1199000 11.70 14028300 12753000
2013 1220745 11.70 14282716 11803897
2014 1330876 11.70 15571249 11698909
2015 1403408 11.70 16419873 11214994
Total 6016250
Table 4. Total cost saved on treatment of JE due to vaccination (in `)
Year Estimated number Cost avoided Cost avoided by Total cost saved due Discount value
of JE cases by the provider the purchaser to vaccination @ 10%
2012 3722 62860746.34 132648358 195509104.3 177735549.4
2013 3954 66778987.38 140916606 207695593.4 171649250.7
2014 4186 70697228.42 149184854 219882082.4 165200663
2015 4418 74615469.46 157453102 232068571.5 144096324.4
Total 658681787
Fig. 2: Graphical representation of annual discounted cost and
benefits. (all costs are in million Rupees)
NVBDCP. Total benefit from the intervention is presented
in Table 4.
Cost benefit analysis
Total discounted cost is ` 6,01,62,504 while total dis-
counted benefit is ` 6,58,681,787. This gives a net dis-
counted value of ` 598.52 million. The cost benefit ratio
is equal to almost 11 which means that for every rupee
invested in vaccination we are getting a return of ` 11
over the period of five years. The IRR is surprisingly high
over the study period and is equal to 291%. Cost of vac-
cination is almost constant over the project period while
benefit from the resources saved is falling more sharply
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cination project. However, certain operational issues are
worth discussing which were not accounted properly in
our model. First with all vaccinations there is a huge cost
associated with storage, distribution, monitoring and dis-
posal of waste safely. Our model does not take into ac-
count these because we assume that introduction of JE
vaccine will not add extra burden of delivery as it is ad-
ministered along with booster dose of DPT. However,
this is not so and substantial cost can be involved which
can bring down the expected value of net benefits. Sec-
ond routine coverage of booster dose of DPT is very low,
only 19% in UP9. This means that even JE vaccine will
also be delivered poorly through routine system. If rou-
tine method is chosen then again high chances are there
that benefits will be low as number of JE cases may re-
main high. If a special drive is designed every year then
the cost may be very high still the intervention may re-
main reasonable.
CONCLUSION
This study is important because it is based on a very
simple model which does away with the need to perform
complex quantification of many health benefits as in a
cost benefit studies of measles vaccination in Japan10.
Only one component itself is giving so high returns that
even in worst scenarios intervention is worth undertak-
ing. However, we can conclude that operational issues
must be addressed correctly so that maximum number of
cases can be avoided albeit at a higher cost of vaccination
so that poorest of the poor can be benefited most.
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